Mumbai, Jan. 31 -- Profit before exceptional items and tax was at Rs 3,792.57 crore in the December 2024 quarter, registering a growth of 23.53% on a YoY basis.

During the quarter, EBITDA stood at Rs 4,009 crore (including other operating revenues), up 15.3% with resulting EBITDA margin of 29.3%

Sales of Formulation in India for Q3 FY25 were at Rs 4,300.4 crore, up 13.8% YoY and accounting for approximately 32% of total consolidated sales.

US Formulation sales were $474 million in Q3 FY25, down 0.7% YoY and accounting for approximately 30% of total consolidated sales.

Formulation sales in emerging markets were $277 million for the third quarter of FY25, growing by 10.1% YoY and accounted for approximately 17% of total consolidated sal...